Research
Hormonal
The 'Dual Intervention Point' (DIP) model proposes that physiological regulation is weak within a 'zone of indifference' (dynamic equilibrium) but becomes strong only when fatness crosses upper or lower intervention points.
Your body's regulatory 'alarm bells' (hunger/satiety signals) may be quiet when you are within a normal weight range (zone of indifference). Strong physiological corrections only happen when you move significantly outside this range (crossing intervention points).
GoodQualifiesMEDIUM confidence
The DIP proposes a zone of indifference where dynamic equilibrium 'regulation' predominates, bounded by upper and lower intervention points beyond which physiological mechanisms are activated.
Why this rating
It is a theoretical model presented as a reconciliation of existing data, awaiting further experimental testing.
Source
Models of body weight and fatness regulation
John R. Speakman et al. · Philosophical Transactions of the Royal Society B Biological Sciences · 2023
DOI 10.1098/rstb.2022.0231
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Body weight regulation is not governed by a single fixed set-point, but rather by a dynamic equilibrium where energy expenditure passively adjusts to match intake, creating a 'zone of indifference' bounded by upper and lower intervention points.Strong
- The evolution of human fat storage levels is driven by a trade-off between starvation risk and predation risk, resulting in an optimum fatness that minimizes total mortality, not maximum fat storage.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →